search icon

    Market Snapshot

    • S&P Futures

      3,819

    • Dow Futures

      30,822

    • Nasdaq Futures

      11,785

    blog search icon

    Aridis Pharmaceuticals, Inc.

    (NASDAQ:ARDS)

    $1.12

    $0.02

    1.82%

    Aridis Pharmaceuticals, Inc. Chart

    ARDS Stock Price Today

    Aridis Pharmaceuticals, Inc. (ARDS) stock rallied over 1.82% intraday to trade at $1.12 a share on NASDAQ. The stock opened with a loss of -2.61% at $1.07 and touched an intraday high of $1.14, rising 1.82% against the last close of $1.1. The stock went to a low of $1.06 during the session.

    Stock Snapshot

    $1.1

    Prev. Close

    19.86 Million

    Market Cap

    $1.06

    Day Low

    $1.07

    Open

    17.7 Million

    Number of Shares

    $1.14

    Day High

    -

    P/E ratio

    -3.44

    EPS (TTM)

    1.02

    Cash Flow per Share

    1.29

    Free Float in %

    -0.30

    Book Value

    25,341

    Volume

    Aridis Pharmaceuticals, Inc. Historical Data

    DateOpenHighLowCloseVolume
    2022-07-06$1.07$1.14$1.06$1.1225,246
    2022-07-05$1.15$1.15$1.04$1.123,400
    2022-07-01$1.13$1.16$1.1$1.128,500
    2022-06-30$1.11$1.11$1.01$1.151,200
    2022-06-29$1.17$1.19$1.11$1.1321,600
    2022-06-28$1.25$1.33$1.13$1.1748,300
    2022-06-27$1.3$1.37$1.21$1.2343,000
    2022-06-24$1.35$1.4$1.25$1.2556,600
    2022-06-23$1.38$1.48$1.31$1.3663,100
    2022-06-22$1.4$1.44$1.35$1.3826,700

    Contact Details

    983 University Avenue
    Building B
    Los Gatos, CA 95032
    United States

    Webiste:ARDS

    408 385 1742

    Company Information

    Employees-

    Beta0.4

    Sales or Revenue1.53 Million

    5Y Sales Change-7.50%

    Fiscal Year Ends2021-12-30

    SectorHealth Care

    IndustryBiotechnology

    About Company

    Aridis Pharmaceuticals, Inc., a late-stage biopharmaceutical company, focuses on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that is in Phase III pivotal trials for the treatment of lung infections resulting from S. aureus alphatoxin. The company is also developing AR-320 is a fully human IgG1 monoclonal antibody targeting S. aureus alpha toxin to treat infections caused by methicillin-resistant Staphylococcus aureus and methicillin-susceptible S. aureus; AR-105, a fully human IgG1 mAb, which is in Phase II trials to target gram-negative bacteria P. aeruginosa; AR-101, a human IgM mAb, which is in Phase IIa clinical trials for the treatment of hospital-acquired pneumonia (HAP)and ventilator-associated pneumonia (VAP) caused by P. aeruginosa serotype O11; AR-401 that is in preclinical stage to treat infections caused by Acinetobacter baumannii; AR-201, a fully human IgG1 mAb preclinical program for respiratory syncytial virus; and AR-501, an anti-infective therapy, which is in Phase I/IIa clinical trial to manage chronic lung infections in cystic fibrosis patients. In addition, it is developing AR-712 and AR-701, a cocktail of two fully human immunoglobulin 1, or IgG1, mAbs, which is in Phase I/II clinical for the treatment of mild to moderate non-hospitalized COVID-19 patients. Aridis Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Los Gatos, California.

    Frequently Asked Questions

    icon

    What is the current Aridis Pharmaceuticals, Inc. (ARDS) stock price?

    Aridis Pharmaceuticals, Inc. (NASDAQ: ARDS) stock price is $1.12 as of the last check on Wednesday, July 6. During the trading session, ARDS stock reached the peak price of $1.14 while $1.06 was the lowest point it dropped to.

    icon

    ARDS's industry and sector of operation?

    The NASDAQ listed ARDS is part of Biotechnology industry that operates in the broader Health Care sector. Aridis Pharmaceuticals, Inc. , a late-stage biopharmaceutical company, focuses on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections.

    icon

    Who are the executives of ARDS?

    Dr. Vu L. Truong
    Founder, CEO & Director
    Dr. Vu L. Truong Ph.D.
    Founder, CEO, Chief Scientific Officer & Director
    Mr. Fred Kurland J.D., M.B.A.
    Chief Financial Officer
    Dr. Hasan Jafri M.D.
    Chief Medical Officer

    icon

    What is the ARDS stock price today?

    ARDS stock traded closed the last session at $1.12, which is $0.02 or 1.82% lower than its previous close of $1.1. ARDS's current trading price is 27.27% lower than its 52-week high of $7.69 where as its distance from 52-week low of 0.88% is -85.44%.

    icon

    How many employees does ARDS have?

    Number of ARDS employees currently stands at -. ARDS operates from 983 University Avenue, Building B, Los Gatos, CA 95032, United States.

    icon

    Link for ARDS official website?

    Official Webiste of $ARDS is: https://www.aridispharma.com

    icon

    How do I contact ARDS?

    ARDS could be contacted at ARDS operates from 983 University Avenue, Building B, Los Gatos, CA 95032, United States, or at phone #408 385 1742 and can also be accessed through its website.

    icon

    How many shares of ARDS are traded daily?

    ARDS stock volume for the day was 25,341 shares while in the previous session number of ARDS shares traded was 25,246 . The average number of ARDS shares traded daily for last 3 months was 58.66 Thousands.

    icon

    How much did ARDS change today?

    The percentage change in ARDS stock occurred in the recent session was 1.82% while the dollar amount for the price change in ARDS stock was $0.02.

    icon

    What price range ARDS stock been trading in?

    In the recent session, the day high for ARDS stock was $1.14 while the low for ARDS stock touched on the day was $1.06.

    icon

    What is the market cap of ARDS currently?

    The market value of ARDS currently stands at 19.86 Million with its latest stock price at $1.12 and 17.7 Million of its shares outstanding.